Osteopontin-c is a selective marker of breast cancer

International Journal of Cancer

Volumn 122, Issue 4, 2008, Pages 889-897

  Mirza, Mana ^a   Shaughnessy, Elizabeth ^a   Hurley, John K ^b   Vanpatten, Kristie A ^b   Pestano, Gary A ^b   He, Bin ^c   Weber, Georg F ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c NORTH SHORE MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Cancer marker; Diagnosis; Immunohistochemistry; Metastasis; Tumor progression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; MOLECULAR MARKER; OSTEOPONTIN; OSTEOPONTIN A; OSTEOPONTIN B; OSTEOPONTIN C; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; ISOPROTEIN;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RNA SPLICING; TUMOR GROWTH; ALTERNATIVE RNA SPLICING; BREAST; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; PROTEIN ISOFORMS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 38349059722     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23204     Document Type: Article

References (25)

1. Chan DW, Sell S. Tumor markers. In: Burtis CA, Ashwood ER, eds. Tietz fundamental of clinical chemistry, 5th ed. Philadelphia: WB Saunders, 2001.390-413.
2. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 2006;11:541-52.
3. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. Philadelphia: Lippinscott Williams & Wilkins; 2000.489-514.
4. Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 2006;3:621-32.
5. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11.
6. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y. Clinical relevance of amphiregulin and VEGF in primary breast cancers. Int J Cancer 2004;111:733-40.
7. Zhang G, He B, Weber GF. Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 2003;23:6507-19.
8. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002;62:3417-27.
9. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-11.
10. Weber GF, Ashkar S. Stress response genes - the genes that make cancer metastasize. J Mol Med 2000;78:404-8.
11. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000;77:487-98.
12. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998;58:5206-15.
13. Kasugai S, Zhang Q, Overall CM, Wrana JL, Butler WT, Sodek J. Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter. Bone Miner 1991;13:235-50.
14. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer. Oncogene 2006;25:2192-202.
15. Benoy IH, Elst H, Van der Auwera I, Van Laere S, van Dam P, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Brit J Cancer 2004;91:1813-20.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 1991;19:403-10.
17. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
18. Bartfay E, Mackillop WJ, Pater JL. Comparing the predictive value of neural network models to logistic regression models on the risk of death for small-cell lung cancer patients. Eur J Cancer Care 2006;15:115-24.
19. Bassi P, Sacco E, De Marco V, Aragona M, Volpe A. Prognostic accuracy of an artificial neural network in patients undergoing radical cystectomy for bladder cancer: a comparison with logistic regression analysis. BJU Int 2007;99:1007-12.
20. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
21. Lehmann EL, D'Abrera HJM. Nonparametrics: statistical methods based on ranks. Englewood Cliffs: Prentice-Hall, 1998.
22. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
23. Hayes DF, Track B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat 1998;52:305-319.
24. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
25. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.